Privium Fund Management B.V. Taysha Gene Therapies, Inc. Transaction History
Privium Fund Management B.V.
- $401 Million
- Q3 2024
A detailed history of Privium Fund Management B.V. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 120,000 shares of TSHA stock, worth $181,200. This represents 0.06% of its overall portfolio holdings.
Number of Shares
120,000
Previous 98,500
21.83%
Holding current value
$181,200
Previous $220,000
9.55%
% of portfolio
0.06%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding TSHA
# of Institutions
118Shares Held
136MCall Options Held
25.9KPut Options Held
24K-
Avoro Capital Advisors LLC New York, NY18.7MShares$28.2 Million0.56% of portfolio
-
Rtw Investments, LP New York, NY14.9MShares$22.6 Million0.48% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$17.7 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$16.4 Million0.3% of portfolio
-
Vr Adviser, LLC New York, NY9MShares$13.6 Million1.87% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $73M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...